Anastrozole Raw Material Powder CAS 120511-73-1

Product Name: Anastrozole Raw Material Powder CAS 120511-73-1

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Specification​: 99%min Anastrozole Powder

Test Method: HPLC

CAS: 120511-73-1

MF: C17H19N5

Sample: Anastrozole Powder

Keywords: Anastrozole Powder,Anastrozole Raw Material,Anastrozole Raw Material Supplier

Anastrozole Description:
The pharmaceutical raw material Anastrozole is used in the treatment of breast cancer. Anastrozole Raw Material Powder is suitable for postmenopausal advanced breast cancer, China Anastrozole Raw Material Powder factory Wholesale Price supply Anastrozole Powder.
Anastrozole Raw Material Powder is a potent and selective triazole aromatase inhibitor, which can inhibit the cytochrome P-450-dependent aromatase to block the biosynthesis of estrogen, which stimulates breast cancer cells main factor of growth. The 50% inhibitory concentration (IC50) value of Anastrozole Raw Material Powder to human placental aromatase is 15nmol/L.

Anastrozole Uses:
Anastrozole Raw Material Powder can comprehensively and effectively reduce the risk of breast cancer recurrence and metastasis, and prolong the disease-free survival of patients; even after completing the standard course of treatment for 4 years, the protective effect of Anastrozole is still sustainable. Anastrozole Powder will become the standard regimen of endocrine adjuvant therapy for breast cancer. Third generation aromatase inhibitors. Anastrozole Powder is indicated for the treatment of postmenopausal patients with advanced breast cancer. Anastrozole Powder is a third generation aromatase inhibitor. For the treatment of postmenopausal patients with advanced breast cancer. A potent and selective triazole aromatase inhibitor that inhibits cytochrome P-450-dependent aromatase to block the biosynthesis of estrogen, which is the main factor that stimulates the growth of breast cancer cells. For the treatment of breast cancer, Anastrozole Powder is especially indicated for advanced breast cancer in postmenopausal women who have relapsed after adjuvant hormone therapy.